Do we have markers to select patients for adjuvant therapies of non-small-cell lung cancer?
Adjuvant platinum-based chemotherapy represents the standard of care in fit stage II and IIIA non-small-cell lung cancer patients after surgical resection. This review discusses current knowledge on molecular prognostic and predictive tumor features for benefit from adjuvant therapies with emphasis on ongoing clinical trials that prospectively assess the biomarker utility. Until the results of these trials are available, use of these markers is not recommended in routine clinical care.